Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CALGB A221101 Principal Investigator: Tran, David
Title: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme (A221101)
Phase: III Disease Site: Brain & Nervous System
Participating Site(s):
 
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to see if taking the study drug, armodafinil, will improve problems with fatigue in patients who have glioblastoma and to see the effects (good and bad) of taking Armodafinil compared to the placebo.
 
More Information:
Internal Protocol Documents (requires Siteman administrative database password)